Narcotic Bowel Syndrome and Opioid-Induced Constipation

Current Gastroenterology Reports

Volumn 16, Issue 10, 2014, Pages 1-11

  Szigethy, Eva ^a   Schwartz, Marc ^a   Drossman, Douglas ^b,c,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Center for Education and Practice of Biopsychosocial Care LLC   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d Drossman Gastroenterology PLLC   (United States)

Author keywords

Alvimopan; Chronic pain mu receptor; Constipation; Hyperalgesia; Lubiprostone; Methylnaltrexone; Naloxegol; Naloxone; Narcotic bowel syndrome; NBS; OIC; Opioid; Opioid abuse; Opioid induced constipation; Oxycodone; Prucalopride; Tapentadol

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BEVENOPRAN; BISACODYL; CLONIDINE; DULOXETINE; GABAPENTIN; KETAMINE; LINACLOTIDE; LUBIPROSTONE; MACROGOL 3350; MAGNESIUM; MEMANTINE; MILNACIPRAN; MORPHINE; NALDEMEDINE; NALOXEGOL; NALOXONE PLUS OXYCODONE; OPIATE; OXYCODONE; PLACEBO; PREGABALIN; PRUCALOPRIDE; SORBITOL; TAPENTADOL; TRICYCLIC ANTIDEPRESSANT AGENT; NARCOTIC ANALGESIC AGENT;

ABDOMINAL PAIN; ANXIETY DISORDER; CHRONIC PAIN; COGNITIVE THERAPY; CONSTIPATION; DETOXIFICATION; DRUG APPROVAL; DRUG EFFICACY; GASTROINTESTINAL MOTILITY; HUMAN; INTESTINE FUNCTION DISORDER; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); NARCOTIC BOWEL SYNDROME; NEUROPATHIC PAIN; NONHUMAN; OPIOID INDUCED CONSTIPATION; PAIN; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOSOCIAL CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WITHDRAWAL SYNDROME; CHEMICALLY INDUCED; SYNDROME;

ABDOMINAL PAIN; ANALGESICS, OPIOID; CHRONIC PAIN; CONSTIPATION; HUMANS; SYNDROME;

EID: 84906723752     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-014-0410-4     Document Type: Review

References (87)

1. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85–92.
2. Mehendale AW, Goldman MP, Mehendale RP. Opioid overuse pain syndrome (OOPS): the story of opioids, prometheus unbound. J Opioid Manag. 2013;9(6):421–38.
3. Manchikanti L, Helm 2nd S, Fellows B, et al. Opioid epidemic in the United States. Pain Phys. 2012;15(3 Suppl):Es9–Es38.
4. Berry PH, Dahl JH. Making pain assessment and management a healthcare system priority through the new JCAHO pain standards. J Pharm Care Pain Symptom Control. 2000;8:5–20.
5. Grunkemeier DM, Cassara JE, Dalton CB, Drossman DA. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5(10):1126–39. quiz 1121–1122. The first comprehensive review of the characteristics, etiology and treatment of narcotic bowel syndrome.
6. Grover M, Drossman DA. Psychopharmacologic and behavioral treatments for functional gastrointestinal disorders. Gastrointest Endosc Clin N Am. 2009;19(1):151–70. vii-viii.
7. Drossman DA, Morris CB, Edwards H, et al. Diagnosis, characterization, and 3-month outcome after detoxification of 39 patients with narcotic bowel syndrome. Am J Gastroenterol. 2012;107(9):1426–40. The first study showing that hospital-based detoxification of patients with narcotic bowel syndrome resulted in reduced pain. Approximately half of the patients reverted to opioid use at 3 months illustrating the need for more intensive post-hospitalization follow-up but the patients who stayed off narcotics showed a greater improvement in pain scores.
8. Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc. 2010;22(4):424–30. e496.
9. Choung RS, Locke 3rd GR, Zinsmeister AR, Schleck CD, Talley NJ. Opioid bowel dysfunction and narcotic bowel syndrome: a population-based study. Am J Gastroenterol. 2009;104(5):1199–204.
10. O’Lenic KS. When should narcotic bowel syndrome be suspected? US Pharm. 2011;36:41–4.
11. Association AP. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
12. Miller AR, North CS, Clouse RE, Wetzel RD, Spitznagel EL, Alpers DH. The association of irritable bowel syndrome and somatization disorder. Ann Clin Psychiatr Off J Am Acad Clin Psychiatr. 2001;13(1):25–30.
13. North CS, Downs D, Clouse RE, et al. The presentation of irritable bowel syndrome in the context of somatization disorder. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2004;2(9):787–95.
14. Phillips K, Clauw DJ. Central pain mechanisms in chronic pain states—maybe it is all in their head. Best Pract Res Clin Rheumatol. 2011;25(2):141–54.
15. Drossman DA, Szigethy E. Narcotic bowel syndrome: 2014 update. Am J Gastroenterol. 2014;in press.
16. Johnston IN, Milligan ED, Wieseler-Frank J, et al. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci Off J Soc Neurosci. 2004;24(33):7353–65.
17. Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Sci World J. 2007;7:98–111. Innovative review showing the mechanisms by which central glial cell activation resulting in the release of pro-inflammatory cytokines is involved in opioid-induced pain. The role of glial modulators to treat neuropathic pain is also discussed.
18. Farmer AD, Ferdinand E, Aziz Q. Opioids and the gastrointestinal tract—a case of narcotic bowel syndrome and literature review. J Neurogastroenterol Motil. 2013;19(1):94–8.
19. King T, Ossipov MH, Vanderah TW, Porreca F, Lai J. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neuro-Signals. 2005;14(4):194–205.
20. Kaplan H, Fields HL. Hyperalgesia during acute opioid abstinence: evidence for a nociceptive facilitating function of the rostral ventromedial medulla. J Neurosci Off J Soc Neurosci. 1991;11(5):1433–9.
21. Burgess SE, Gardell LR, Ossipov MH, et al. Time-dependent descending facilitation from the rostral ventromedial medulla maintains, but does not initiate, neuropathic pain. J Neurosci Off J Soc Neurosci. 2002;22(12):5129–36.
22. Hutchinson MR, Northcutt AL, Hiranita T, et al. Opioid activation of toll-like receptor 4 contributes to drug reinforcement. J Neurosci Off J Soc Neurosci. 2012;32(33):11187–200.
23. Hutchinson MR, Watkins LR. Why is neuroimmunopharmacology crucial for the future of addiction research? Neuropharmacology. 2014;76 Pt B:218–27.
24. Fujio M, Nakagawa T, Sekiya Y, et al. Gene transfer of GLT-1, a glutamate transporter, into the nucleus accumbens shell attenuates methamphetamine- and morphine-induced conditioned place preference in rats. Eur J Neurosci. 2005;22(11):2744–54.
25. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Phys. 2011;14(2):145–61.
26. Lee YS, Muthu D, Hall SM, et al. Discovery of amphipathic dynorphin a analogues to inhibit the neuroexcitatory effects of dynorphin a through bradykinin receptors in the spinal cord. J Am Chem Soc. 2014;136(18):6608–16.
27. Xie JY, Herman DS, Stiller CO, et al. Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. J Neurosci Off J Soc Neurosci. 2005;25(2):409–16.
28. Wagner KM, Roeder Z, Desrochers K, Buhler AV, Heinricher MM, Cleary DR. The dorsomedial hypothalamus mediates stress-induced hyperalgesia and is the source of the pronociceptive peptide cholecystokinin in the rostral ventromedial medulla. Neuroscience. 2013;238:29–38.
29. Kurlander JE, Drossman DA. Diagnosis and treatment of narcotic bowel syndrome. Nat Rev Gastroenterol Hepatol. 2014.
30. Lobmaier P, Gossop M, Waal H, Bramness J. The pharmacological treatment of opioid addiction—a clinical perspective. Eur J Clin Pharmacol. 2010;66(6):537–45.
31. Liu KS, Chen SJ, Chen YW, Sung KC, Wang JJ. A dose-response study on the efficacy of tricyclic antidepressants on reducing morphine-withdrawal symptoms. Acta Anaesthesiol Taiwan Off J Taiwan Soc Anesthesiol. 2013;51(1):18–21.
32. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol WJG. 2009;15(13):1548–53.
33. Hutchinson MR, Loram LC, Zhang Y, et al. Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activity. Neuroscience. 2010;168(2):551–63. A study in mice showing that tricyclic antidepressants selectively modulate Toll-like receptors involved in the pain and may enhance the analgesic efficacy of opioids.
34. Bellingham GA, Peng PW. Duloxetine: a review of its pharmacology and use in chronic pain management. Reg Anesth Pain Med. 2010;35(3):294–303.
35. Onal A, Parlar A, Ulker S. Milnacipran attenuates hyperalgesia and potentiates antihyperalgesic effect of tramadol in rats with mononeuropathic pain. Pharmacol Biochem Behav. 2007;88(2):171–8.
36. Wu N, Chen SY, Hallett LA, et al. Opioid utilization and health-care costs among patients with diabetic peripheral neuropathic pain treated with duloxetine vs. other therapies. Pain Pract Off J World Inst Pain. 2011;11(1):48–56.
37. Andrews JS, Wu N, Chen SY, Yu X, Peng X, Novick D. Real-world treatment patterns and opioid use in chronic low back pain patients initiating duloxetine versus standard of care. J Pain Res. 2013;6:825–35.
38. Dworkin RH, Corbin AE, Young Jr JP, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60(8):1274–83.
39. Lee KJ, Kim JH, Cho SW. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22(10):981–8.
40. Arnold LM, Crofford LJ, Martin SA, Young JP, Sharma U. The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med (Malden, Mass). 2007;8(8):633–8.
41. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain Off J Am Pain Soc. 2008;9(9):792–805.
42. Narita N, Kumar N, Cherkas PS, et al. Systemic pregabalin attenuates sensorimotor responses and medullary glutamate release in inflammatory tooth pain model. Neuroscience. 2012;218:359–66.
43. Harris RE, Napadow V, Huggins JP, et al. Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients. Anesthesiology. 2013;119(6):1453–64.
44. Hackworth RJ, Tokarz KA, Fowler IM, Wallace SC, Stedje-Larsen ET. Profound pain reduction after induction of memantine treatment in two patients with severe phantom limb pain. Anesth Analg. 2008;107(4):1377–9.
45. Grande LA, O’Donnell BR, Fitzgibbon DR, Terman GW. Ultra-low dose ketamine and memantine treatment for pain in an opioid-tolerant oncology patient. Anesth Analg. 2008;107(4):1380–3.
46. Phillips K, Clauw DJ. Central pain mechanisms in the rheumatic diseases: future directions. Arthritis Rheum. 2013;65(2):291–302.
47. Palsson OS, Whitehead WE. Psychological treatments in functional gastrointestinal disorders: a primer for the gastroenterologist. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013;11(3):208–16. quiz e222-203.
48. Szigethy E, Bujoreanu SI, Youk A, et al. Randomized efficacy trial of two psychotherapies for depression in youth with inflammatory bowel disease. J Am Acad Child Adolesc. 2014;in press.
49. Mawdsley JE, Jenkins DG, Macey MG, Langmead L, Rampton DS. The effect of hypnosis on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Am J Gastroenterol. 2008;103(6):1460–9.
50. Schoen M, Nowack K. Reconditioning the stress response with hypnosis CD reduces the inflammatory cytokine IL-6 and influences resilience: a pilot study. Complement Ther Clin Pract. 2013;19(2):83–8.
51. Camilleri M, Drossman DA, Becker G, Webster LR, Davies AN, Mawe GM. Unmet needs in opioid induced constipation. Neurogastroenter Motil, 2014, in press.
52. Dunn KM, Saunders KW, Rutter CM, et al. Opioid precriptions for chronic pain and overdose: a cohort study. Ann Int Med. 2010;152(2):85–92.
53. Kalso E, Edwards JE, Moore, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372–80.
54. Benyamin R, Trescot AM, Datta S, et al. Opiod complications and side effects. Pain Phys. 2008;11(2 Suppl):S105–20.
55. Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastro. 2011;106(5):835–42.
56. Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett. 2004;361(1–3):192–5.
57. Ishihara M, Ikesue H, Matsunaga H, et al. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain. 2012;28(5):373–81. A large retrospective study in patients with cancer pain. The study showed that prophylactic use of osmotic laxatives decreased constipation by almost half, although early antiemetic use did not decrease nausea.
58. Myotoku M, Nakanashi A, Kanematsu M, et al. Reduction of opioid side effects by prophylactic measures of palliative care team may result in improved quality of life. J Palliat Med. 2010;13(4):401–6.
59. Dipalma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007;102(7):1436–41.
60. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103(1):170–7.
61. Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome—results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29(3):329–41.
62. Cryer B, Katz S, Vallejo R, Popescu A, Ueno R. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med. 2014 Apr 9. [Epub ahead of print]
63. Irving G, Penzes J, Ramjattan B, et al. A randomized, placebo-controlled phase 3 trial (study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain. 2011;12(2):175–84.
64. Jansen J-P, Lorch D, Langan, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. The Journal of Pain. 2011;12(2):185–93.
65. Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(10):1566–74. An up to date meta-analysis of the clinical trials data on methylnaltrexone, alvimopan, and oxycodone/naloxone. A systematic review of other medical therapies is included.
66. Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011;12(5):554–62.
67. Rauck RL, Peppin JP, Israel RJ, et al. Oral methylnaltrexone for the treatment of opioid-induced constipation in patients with noncancer pain. Gastroenterology. 2012;142(5, Supp1):S160.
68. Hartrick C, Van Hove I, Stegmann J-U, Oh C, Upmalis D. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther. 2009;31(2):260–71.
69. Gálvez R, Schäfer M, Hans G, Falke D, Steigerwald I. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study. Adv Ther. 2013;30(3):229–59.
70. Etropolski M, Kelly K, Okamoto A, Rauschkolb C. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Adv Ther. 2011;28(5):401–17.
71. Lowenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother. 2009;10(4):531–43.
72. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13(1):56–64.
73. Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008;24(12):3503–12.
74. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014 Jun 4. [Epub ahead of print]
75. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358(22):2344–54.
76. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001;120(2):354–60.
77. Sloots CE, Rykx A, Cools M, Kerstens R, De Pauw M. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci. 2010;55(10):2912–21.
78. Ketwaroo GA, Cheng V, Lembo A. Opioid-induced bowel dysfunction. Curr Gastroenterol Rep. 2013;15(9):344–50.
79. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers—United States, 1999--2008. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487–92. Governmental report quantifies the marked increase in US opioid prescribing over the past decade and the resulting toll of morbidity and mortality.
80. Deshpande A, Furlan A, Mailis-Gagnon A, Atlas S, Turk D. Opioids for chronic low-back pain. Cochrane Database Syst Rev. 2007;3, CD004959.
81. Franklin GM, Rahman EA, Turner JA, Daniell WE, Fulton-Kehoe D. Opioid use for chronic low back pain: a prospective, population-based study among injured workers in Washington state, 2002–2005. Clin J Pain. 2009;25(9):743–51.
82. Franklin GM, Stover BD, Turner, et al. Early opioid prescription and subsequent disability among workers with back injuries: the Disability Risk Identification Study Cohort. Spine. 2008;33(2):199–204.
83. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012;107(9):1409–22.
84. Kobus AM, Smith DH, Morasco BJ, Johnson ES, Yang X, Petrik AF, et al. Correlates of higher-dose opioid medication use for low back pain in primary care. J Pain. 2012;13(11):1131–8.
85. Chou R, Shekelle P. Will this patient develop disabling low back pain? JAMA. 2010;303(13):1295–1302.87.
86. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8(7):573–82.
87. Hill JC, Whitehurst DG, Lewis M, et al. Comparison of stratified primary care management for low back pain with current best practice (STarT Back): a randomised controlled trial. Lancet. 2011;378(9802):1560–71.